One of the most popular and well-known names in the biotech world is definitely Biogen (BIIB-Analyst Report). This large cap stock has been a staple of investor portfolios in the biotechnology space for some time, while it is also one of the behemoths of the sector, closing in on $100 billion in market cap.BIIB might be due for a breather […]
SummaryOvaScience, Sarpeta Therapeutics, Ziopharm Oncology and Keryx Biopharmaceuticals all have a short interest above 20%.
These small cap biotech companies provide attractive characteristics for fundamental weakness through liquidity needs, no revenue and a higher fail rate.
Given these common variables, there is strong indication that a large Marco short strategy has been put in place.
This large short position provides opportunities for contrarian […]
The Celgene Corporation (CELG – Analyst Report) – Juno Therapeutics’ (JUNO – Analyst Report) immunotherapy deal worth at least a billion dollars was the main story in the biotech sector this week. While concerns are being raised about the high price tag, the deal just goes to show the growing interest in the field of immunotherapy. Meanwhile, quite a few […]
Some traders like to gamble on big news events that could have a dramatic effect on a particular stock. For example, the release of a company’s earnings report could cause an underlying stock to jump to new highs or drop to significant lows. While this may not interest all investors, it does prove to be a point of intrigue for […]
Epizyme (NASDAQ:EPZM)On June 22, 2015 shares of Epizyme were up about 27% after the company announced that it had obtained positive phase 1 results in patients with Non-Hodgkin’s Lymphoma — NHL. The company used its drug known as EPZ-6438, which is also known as tazemetostat to treat these patients with NHL. Epizyme has developed this drug to treat these NHL […]
Biotech stocks, which have risen 550% since the depths of the recession, are now prime targets of short sellers betting they will collapse in grand fashion. “Of any part of the market, this is the one with the most bubble-like characteristics, without question.”Bubble Watch: Biotech Edition Bubble Watch: Biotech Edition Bubble Watch: Biotech EditionThe financial markets have been on the […]
Biotech stocks, which have risen 550% since the depths of the recession, are now prime targets of short sellers betting they will collapse in grand fashion. “Of any part of the market, this is the one with the most bubble-like characteristics, without question.”Bubble Watch: Biotech Edition Bubble Watch: Biotech Edition Bubble Watch: Biotech EditionThe financial markets have been on the […]
Avalanche Biotech (NASDAQ:AAVL)Shares of Avalanche Biotech fell as much as 40% in after-hours trading on June 15, 2015 after the company announced results from its phase 2 wet-age related macular degeneration — wet-AMD — trial. The drop is huge but many investors should be assured that the drop was justified because the results were mediocre at best. In addition if […]
Kyle Anderson: Spending on cancer treatment has been skyrocketing globally. According to the IMS Institute of Health, spending on cancer topped $100 billion globally in 2014. That was a 10% increase from 2013.That’s why many biotech stocks tied to cancer treatments have seen triple-digit gains in the last two years.Have you ever wondered how billionaires continue to get RICHER, while the rest of […]
While the stocks are not cheap, they’re not expensive, he added. What investors are paying for is high quality growth and high quality earnings.Read MoreCramer: Secret pattern to unlocking biotech richesIn fact, he thinks people have underappreciated biotech’s “fantastic” margins, noting that the companies now have 50 to 70 percent operating margins and “tons of real cash flow.””These are real […]
